全球鐵凋亡標靶治療市場：市場機會、治療方法、技術開發平台和臨床試驗展望（2026年）

全球鐵凋亡標靶治療市場 - 市場機會、治療方法、技術開發平台和臨床試驗展望（2026年）研究結果和亮點：

• 全球與區域市場機會分析
• 臨床試驗中領先療法的見解：超過 15 種療法
• 鐵凋亡標靶治療臨床試驗趨勢（依公司、國家、適應症和階段劃分）
• 鐵凋亡標靶治療臨床趨勢與特定適應症創新展望
• 關鍵臨床試驗啟動與完成年份
• FDA 和 EMA 認定洞察：孤兒藥、快速通道
• 鐵凋亡治療開發的技術平台與方法

需求鐵凋亡標靶治療及本報告的意義

鐵凋亡標靶治療已成為治療多種疾病（包括癌症、神經退化性疾病和缺血性損傷）的新方法。鐵凋亡是一種受控細胞死亡，由鐵依賴性和脂質過氧化驅動的機制介導，能夠選擇性地清除病變細胞，提供了一種不同於化療和免疫療法的治療途徑。這項特性使其對膠質母細胞瘤和三陰性乳癌等抗藥性癌症特別有效，因為傳統療法通常對這些癌症無效。

由於現有療法的局限性，人們需要基於鐵凋亡的療法。化療和免疫療法雖然有效，但隨著時間的推移容易產生抗藥性，並且通常伴隨全身毒性。因此，鐵凋亡靶向癌細胞特有的代謝通路，為更精確地誘導細胞死亡並最大限度地減少對正常組織的附帶損傷提供了一種很有前景的方法。

本報告目的是幫助製藥公司、投資者、研究機構和其他利害關係人了解鐵凋亡的當前治療格局。報告基於進行中的臨床試驗、技術平台和主要參與者，重點闡述了鐵凋亡作為重要治療標靶的巨大潛力。

本報告包含的臨床研究和試驗見解

本報告全面分析了針對鐵凋亡的臨床研究和試驗，涵蓋各個治療領域，特別是在腫瘤領域，包括單藥治療和聯合治療。特別值得注意的是，多項研究探索鐵凋亡誘導劑與傳統療法（如化療、免疫療法和標靶療法）的聯合作用。這些聯合療法目的是克服腫瘤抗藥性並提高治療反應，確保患者獲得更好的治療效果。

本報告也涵蓋了其他治療領域的臨床試驗，包括阿茲海默症和帕金森氏症等神經退化性疾病。在這些疾病中，鐵凋亡與氧化壓力導致的細胞死亡過程密切相關。早期臨床前資料表明，鐵凋亡抑制劑可能具有神經保護作用，能夠預防神經元損傷並保護腦功能。本報告也深入分析了臨床試驗申辦方，包括大型製藥公司、生技公司和學術機構。這有助於利害關係人識別推動創新的關鍵參與者，並評估區域趨勢，尤其是在中國等新興市場，儘管存在監管障礙，但鐵凋亡療法的應用加速發展。

從事鐵凋亡標靶療法研發的主要公司

包括PTC Therapeutics、BeBetter Med和住友製藥在內的行業主要參與者正致力於開發鐵凋亡標靶療法。這些公司開發用於治療癌症和神經退化性疾病等疾病的鐵凋亡誘導劑和抑制劑。例如，PTC Therapeutics 目前專注於實驗性藥物 "vatiquinone" ，該藥物靶向氧化壓力通路，並在癌症和Friedreich氏失調症的臨床試驗中顯示出積極結果。

本報告揭示了這些公司的研發策略和產品線，使利害關係人能夠更清晰地了解該領域的未來發展。基於後期臨床試驗的進展，基於鐵凋亡的療法很可能即將實現商業化。此外，與新興生物技術公司和學術機構的合作產生創新方法，例如奈米載體系統和雙效分子，這些方法有可能進一步提高鐵凋亡療法的療效和特異性。

報告：確定鐵凋亡標靶療法的未來發展方向

本報告預測，鐵凋亡標靶療法將繼續快速發展，尤其是在個人化醫療領域。對生物標記的深入研究有望更準確地預測患者的治療反應，並實現更個人化、更有效且副作用更少的治療。將鐵凋亡誘導劑與免疫療法、放射療法和標靶療法結合，以提高癌症治療效果，也成為一種趨勢。此外，奈米顆粒等藥物遞送系統的進步有望提高這些療法的靶向性和生物利用度。

隨著臨床試驗的不斷進行和投資的增加，基於鐵凋亡的療法前景光明。這些療法甚至可能徹底改變癌症和其他細胞死亡相關疾病的治療方式。

目錄

第1章 研究方法

第2章 利用鐵凋亡進行治療開發

• 鐵凋亡標靶治療概述
• 鐵死在治療應用上的發展歷程

第3章 臨床環境中調控鐵凋亡的必要性

第4章 鐵凋亡的新型診斷與預後潛力

第5章 標靶與誘導鐵凋亡的策略

• 小分子
• 藥物重定位
• 光動力療法
• 細胞外囊泡
• 細胞治療
• 奈米顆粒

第6章 依適應症的鐵凋亡標靶治療：臨床趨勢與創新

• 癌症
• 自體免疫疾病與發炎性疾病
• 微生物感染性疾病
• 神經系統疾病與精神疾病
• 心血管疾病

第7章 鐵凋亡標靶治療臨床試驗的全球概覽

• 依階段劃分
• 依國家劃分
• 依公司劃分
• 依適應症劃分
• 依優先狀態劃分

第8章 鐵凋亡標靶治療臨床試驗的全球洞察（依公司、國家、適應症和階段）

• 研究
• 臨床前
• I期
• I/II期
• II期
• III期
• 註冊前
• 註冊

第9章 全球鐵凋亡標靶治療市場 - 趨勢與發展

• 當前市場概覽
• 未來市場預測

第10章 伊福司他 - 首個獲準的鐵凋亡標靶治療藥物

第11章 鐵凋亡標靶治療市場趨勢（依地區劃分）

• 美國
• 中國
• 歐洲
• 韓國

第12章 鐵凋亡候選藥物的監管認定物質

第13章 基於鐵凋亡療法的合理聯合策略

• 與傳統療法合併應用
• 與免疫療法合併應用
• 與光動力療法和磁場療法合併應用
• 與奈米科技聯合應用

第14章 鐵凋亡療法開發的技術平台與方法

• 鐵凋亡與發炎平台 - PTC Therapeutics
• MIT平台 - MitoImmune
• 非病毒基因治療方法 - PulseSight

第15章 全球鐵凋亡標靶治療市場動態

• 市場驅動因素
• 市場挑戰

第16章 競爭格局

• FELIQS
• FerroptoCure
• MitoImmune Therapeutics
• Prothegen
• PTC Therapeutics
• PulseSight Therapeutics
• Rubedo Life Sciences
• Sumitomo
• Tharimmune
• Vandria

Global Ferroptosis Targeting Therapy Market Opportunity, Therapeutic Approaches, Technology Development Platforms & Clinical Trials Insight 2026 Report Findings & Highlights:

• Global & Regional Market Opportunity Analysis
• Clinical Trials Insight On Key Therapies In Trials: > 15 Therapies
• Ferroptosis Targeting Therapies Clinical Trials Insight By Company, Country, Indication & Phase
• Ferroptosis Targeting Therapies Clinical Trends & Innovations Outlook By Indications
• Key Clinical Studies Initiation & Completion Year Overview
• FDA & EMA Designations Insight: Orphan, Fast Track
• Technological Platforms & Approaches For Ferroptosis Therapeutic Development

Ferroptosis Targeted Therapies Need & Why This Report?

Ferroptosis targeted therapies have emerged as a novel approach to the treatment of several diseases, including cancer, neurodegenerative disorders and ischemic injuries. Ferroptosis is a type of regulated cell death that is driven by iron dependent and lipid peroxidation driven mechanisms, providing a different approach to the selective elimination of diseased cells than chemotherapy or immunotherapy. This makes it an especially useful approach for drug resistant cancers, such as glioblastoma and triple negative breast cancer, for which conventional treatment modalities commonly fail.

The need for ferroptosis based therapies emanates from the shortcomings of the current treatment modalities. Chemotherapy and immunotherapy, though effective, usually result in resistance over time, with their attendant systemic toxicity. Ferroptosis, therefore, with its targeted action on metabolic pathways unique to cancer cells, promises a more precise way to induce cell death with reduced collateral damage to normal tissues.

This report is designed to help stakeholders understand the current therapeutic landscape of ferroptosis, including pharmaceutical companies, investors, and research institutions. Based on ongoing clinical trials, technological platforms, and key players, the report has indicated the expanding potential of ferroptosis as a vital target for therapeutic development.

Clinical Studies & Trials Insight Included In Report

This report comprehensively analyzes ongoing clinical studies and trials targeting ferroptosis across therapeutic areas. This includes both monotherapies and combination therapies, particularly in cancer treatment. Most notably, several studies are considering the efficacy of combining the administration of ferroptosis inducers with more traditional therapies, such as chemotherapy, immunotherapy, and targeted treatments. These combinations have been developed to circumvent tumor resistance, improve therapeutic response, and thus ensure better outcomes for patients.

The report also encompasses clinical trials in other therapeutic areas, including neurodegenerative diseases like Alzheimer's and Parkinson's, where ferroptosis has been implicated in the cell death process due to oxidative stress. Early preclinical data suggests that inhibitors of ferroptosis may have neuroprotective effects, which can prevent neuronal damage and maintain brain function. Furthermore, the report provides insight into trial sponsors, including major pharmaceutical companies, biotech firms, and academic institutions. This helps stakeholders to identify the key players driving innovation and to assess the geographical landscape, especially emerging markets such as China, where adoption of ferroptosis therapies is accelerating even against a backdrop of regulatory hurdles.

Leading Companies Engaged In R&D Of Ferroptosis Targeted Therapies

The leading companies in the industry have surged in developing therapies targeted at ferroptosis, including PTC Therapeutics, BeBetter Med, and Sumitomo Pharma. These firms are developing inducers and inhibitors of ferroptosis for use in oncology, among other indications, and neurodegenerative diseases. For instance, a company named PTC Therapeutics is currently focused on vatiquinone, an experimental medication that targets oxidative stress pathways and has shown positive results from clinical trials for cancers and Friedreich's ataxia.

The report sheds light into the R&D strategies and pipelines of these companies, hence allowing stakeholders to have a clear view of where the field is heading. Based on their progress in late-phase trials, there is a high possibility that ferroptosis based therapies are close to commercialization. Additionally, emerging biotech firms and academic collaborations contribute to innovative approaches such as nanocarrier systems and dual-action molecules that may further enhance the efficacy and specificity of ferroptosis therapies.

Report Indicating Future Direction Of Ferroptosis-targeted Therapies

The report predicts that therapies targeting ferroptosis will continue to rapidly evolve, particularly in personalized medicine, and that deeper research into biomarkers will predict patient response with much more personalized, effective treatments that have fewer side effects. It also presents the trend of an increasing number of studies combining ferroptosis inducers with immunotherapy, radiation, and targeted therapies to enhance cancer treatment efficacy. Moreover, advancements in drug delivery systems, such as nanoparticles, are foreseen to enhance targeting and the bioavailability of these therapies.

With continuous clinical trials and increasing investment, the future of treatments based on ferroptosis looks bright; such treatments may even revolutionize the treatment of cancer and other diseases associated with cell death.

Table of Contents

1. Research Methodology

2. Harnessing Ferroptosis In Therapeutic Development

• 2.1 Outline Of Ferroptosis Targeting Therapy
• 2.2 Chronological Development Of Ferroptosis In Therapeutic Applications

3. Therapeutic Need For Ferroptosis Modulation In Clinical Practice

4. Emerging Diagnostic & Prognostic Potential Of Ferroptosis

5. Strategies For Targeting & Inducing Ferroptosis

• 5.1 Small Molecules
• 5.2 Drug Repurposing
• 5.3 Photodynamic Therapy
• 5.4 Extracellular Vesicles
• 5.5 Cell Therapies
• 5.6 Nanoparticles

6. Ferroptosis Targeting Therapy By Indications: Clinical Trends & Innovations

• 6.1 Cancer
• 6.2 Autoimmune & Inflammatory Diseases
• 6.3 Microbial Infections
• 6.4 Neurological & Psychiatric Disorders
• 6.5 Cardiovascular Diseases

7. Global Ferroptosis Targeting Therapy Clinical Trials Overview

• 7.1 By Phase
• 7.2 By Country
• 7.3 By Company
• 7.4 By Indication
• 7.5 By Priority Status

8. Global Ferroptosis Targeting Therapy Clinical Trials Insight By Company, Country, Indication & Phase

• 8.1 Research
• 8.2 Preclinical
• 8.3 Phase I
• 8.4 Phase I/II
• 8.5 Phase II
• 8.6 Phase III
• 8.7 Preregistration
• 8.8 Registration

9. Global Ferroptosis Targeted Therapy Market - Trends & Developments

• 9.1 Current Market Overview
• 9.2 Future Market Forecast

10. Ifupinostat - 1st Approved Ferroptosis Targeting Therapy

11. Ferroptosis Targeting Therapy Market Trends By Region

• 11.1 US
• 11.2 China
• 11.3 Europe
• 11.4 South Korea

12. Ferroptosis Candidates Granted Regulatory Designations

13. Rational Combination Strategies For Ferroptosis Based Therapies

• 13.1 Combinations With Conventional Therapies
• 13.2 Combinations With Immunotherapy
• 13.3 Combinations With Photodynamic Therapies & Magnetic Fields
• 13.4 Combinations With Nanotechnology

14. Technological Platforms & Approaches For Ferroptosis Therapeutic Development

• 14.1 Ferroptosis & Inflammation Platform - PTC Therapeutics
• 14.2 MIT Platform - MitoImmune
• 14.3 Non-Viral Gene Therapy Approach - PulseSight

15. Global Ferroptosis Targeting Therapy Market Dynamics

• 15.1 Market Drivers
• 15.2 Market Challenges

16. Competitive Landscape

• 16.1 FELIQS
• 16.2 FerroptoCure
• 16.3 MitoImmune Therapeutics
• 16.4 Prothegen
• 16.5 PTC Therapeutics
• 16.6 PulseSight Therapeutics
• 16.7 Rubedo Life Sciences
• 16.8 Sumitomo
• 16.9 Tharimmune
• 16.10 Vandria

List of Figures

• Figure 2-1: Indications Linked To Ferroptosis
• Figure 2-2: Timeline Of Key Discoveries In Regulated Cell Death
• Figure 3 1: Clinical Necessity For Ferroptosis Targeting Therapies
• Figure 4-1: Ferroptosis As Diagnostic & Prognostic Marker
• Figure 5-1: Therapeutic Modalities For Ferroptosis
• Figure 6-1: Plant Products Used To Induce Ferroptosis in Cancer Treatment
• Figure 6-2: CNSI-Fe(II) Phase I (NCT06048367) Study - Initiation & Completion Year
• Figure 6-3: N6F11 - Mode Of Action
• Figure 6-4: Capella Phase II (NCT05493800) Study - Initiation & Completion Year
• Figure 6-5: PTC743-NEU-003e-FA Phase III (NCT05515536) Study - Initiation & Completion Year
• Figure 7-1: Global - Ferroptosis Targeting Therapy Clinical Trials By Phase (Numbers), 2026
• Figure 7-2: Global - Ferroptosis Targeting Therapy Clinical Trials By Country (Numbers), 2026
• Figure 7-3: Global - Ferroptosis Targeting Therapy Clinical Trials By Company (Numbers), 2026
• Figure 7-4: Global - Ferroptosis Targeting Therapy Clinical Trials By Indication (Numbers), 2026
• Figure 7-5: Global - Ferroptosis Targeting Therapy Clinical Trials By Priority Status (Numbers), 2026
• Figure 9-1: Ferroptosis-Targeting Therapy Market - Future Opportunities
• Figure 14-1: PulseSight - Technology
• Figure 15-1: Global Ferroptosis Targeting Therapy Market - Drivers
• Figure 15-2: Global Ferroptosis Targeting Therapy Market - Challenges

List of Tables

• Table 4-1: Ferroptosis-Related Biomarkers: Diagnostic & Prognostic Roles Across Diseases
• Table 5-1: Therapeutic Compounds Inducing/Inhibiting Ferroptosis
• Table 6-1: Cancer - Reversing Therapy Resistance By Ferroptosis Inducing Compounds
• Table 6-2: Autoimmune & Inflammatory Disease - Role Of Ferroptosis
• Table 6-3: Autoimmune & Inflammatory Disease - Anti-Ferroptosis Therapeutic Options
• Table 6-4: Ferroptosis Effector & Its Mechanism In Nervous System Disorders
• Table 6-5: Role Of Ferroptosis In Cardiovascular Diseases
• Table 12-1: Ferroptosis Targeting Therapies Granted Regulatory Designations